SOBIS logo

Swedish Orphan Biovitrum BATS-CHIXE:SOBIS Stock Report

Last Price

SEK 327.10

Market Cap

SEK 109.9b

7D

0%

1Y

12.6%

Updated

10 Jan, 2025

Data

Company Financials +

Swedish Orphan Biovitrum AB (publ)

BATS-CHIXE:SOBIS Stock Report

Market Cap: SEK 109.9b

SOBIS Stock Overview

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details

SOBIS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance4/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Swedish Orphan Biovitrum AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Swedish Orphan Biovitrum
Historical stock prices
Current Share PriceSEK 327.10
52 Week HighSEK 344.80
52 Week LowSEK 246.10
Beta0.23
1 Month Change0%
3 Month Change8.92%
1 Year Change12.56%
3 Year Change77.92%
5 Year Change74.83%
Change since IPO856.43%

Recent News & Updates

Recent updates

Shareholder Returns

SOBISGB BiotechsGB Market
7D0%-3.8%-0.3%
1Y12.6%-25.1%4.9%

Return vs Industry: SOBIS exceeded the UK Biotechs industry which returned -23.5% over the past year.

Return vs Market: SOBIS exceeded the UK Market which returned 6.6% over the past year.

Price Volatility

Is SOBIS's price volatile compared to industry and market?
SOBIS volatility
SOBIS Average Weekly Movementn/a
Biotechs Industry Average Movement9.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: SOBIS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine SOBIS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19391,814Guido Oelkerswww.sobi.com

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.

Swedish Orphan Biovitrum AB (publ) Fundamentals Summary

How do Swedish Orphan Biovitrum's earnings and revenue compare to its market cap?
SOBIS fundamental statistics
Market capSEK 109.90b
Earnings (TTM)SEK 3.51b
Revenue (TTM)SEK 25.44b

30.6x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SOBIS income statement (TTM)
RevenueSEK 25.44b
Cost of RevenueSEK 5.44b
Gross ProfitSEK 19.99b
Other ExpensesSEK 16.48b
EarningsSEK 3.51b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)10.23
Gross Margin78.60%
Net Profit Margin13.82%
Debt/Equity Ratio47.1%

How did SOBIS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 16:08
End of Day Share Price 2024/11/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander LindströmABG Sundal Collier
Shirley ChenBarclays
Rosie TurnerBarclays